Chemo Io News Today

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.

Expert oncologist Benjamin P. Levy, MD, shares his excitement for an upcoming program centered on recent data with selpercatinib versus pembrolizumab in patients with non-small cell lung cancer following ESMO 2023.

Experts address the impact of platinum shortages, 4-cycle platinum chemotherapy, and available treatments beyond platinum chemotherapy.

Experts deliberate on the optimal timing of chemoimmunotherapy and if it should be before or after surgery.

Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, review the frontline treatment armamentarium available to patients with follicular lymphoma.

A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.

A broad view of the current treatment paradigm for relapsed/refractory follicular lymphoma and how the field has been evolving.

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).